IL18 and Alzheimer disease: In agreement with these findings, our in vivo experiments found that ginkgolide treatment resulted in decreased expression levels of NLRP3, ASC, and caspase-1, as well as reduced production of IL-1β and IL-18 in the AD mice brain, indicating the protective effects of ginkgolide through inactivation of the NLRP3/caspase-1 pathway, possibly in microglia.